Daily Endocrinology Research Analysis
Analyzed 79 papers and selected 3 impactful papers.
Summary
Analyzed 79 papers and selected 3 impactful articles.
Selected Articles
1. Association between type 2 diabetes and site-specific fracture risk: A systematic review and meta-analysis of cohort studies including over 13 million participants.
Across 22 cohort studies with over 13 million individuals, type 2 diabetes was associated with a 25% higher overall fracture risk, with the strongest excess risk in lower limb sites. Associations were stronger in prospective designs, in women, and with longer diabetes duration, underscoring the need for site-specific fracture prevention in T2D.
Impact: This comprehensive meta-analysis quantifies site-specific skeletal risk in T2D at unprecedented scale, informing targeted screening and prevention beyond hip fractures. It provides robust epidemiologic evidence to refine osteoporosis risk assessment in diabetes care.
Clinical Implications: In patients with T2D, incorporate site-specific fracture risk into assessment (e.g., lower limb focus) and consider earlier screening, fall prevention, vitamin D/calcium optimization, and antiresorptive or anabolic therapy in high-risk subgroups, especially women and those with longer disease duration.
Key Findings
- Type 2 diabetes increased overall fracture risk by 25% (HR 1.25; 95% CI 1.20–1.31).
- Risk was highest for lower limb fractures (HR 1.43), followed by upper limb (HR 1.29) and fragility fractures (HR 1.14).
- Associations were stronger in prospective studies, in women, and with longer diabetes duration; higher female proportion amplified lower-limb risk in meta-regression.
Methodological Strengths
- Large-scale meta-analysis with 22 cohort studies and 13,074,868 participants
- PROSPERO-registered protocol and random-effects modeling with meta-regression
Limitations
- Heterogeneity across cohorts and outcome definitions
- Observational design limits causal inference and residual confounding is possible
Future Directions: Standardize fracture definitions and adjust for diabetes treatments, glycemic control, neuropathy, and falls to refine risk estimates; develop T2D-specific fracture risk tools and test targeted prevention in pragmatic trials.
OBJECTIVE: This review aimed to quantify the association between Type 2 Diabetes (T2D) and the risk of fracture at various anatomical sites by synthesising data from cohort studies. METHODS: A systematic search was conducted across Medline, Embase, CINAHL and Web of Science databases, from inception to 10 June 2025. We estimated pooled hazard ratios (HRs) with corresponding 95% confidence intervals using random-effects models. This study is registered with PROSPERO (CRD42024548795). RESULTS: This meta-analysis of 22 studies, selected from 6534 screened studies, assessed a total of 13,074,868 individuals (2,644,443 people with T2D and 10,430,425 without T2D). People with T2D have a 25% increased risk of fractures (all anatomical sites) compared to individuals without T2D (HR: 1.25; 95% CI: 1.20 to 1.31). T2D was significantly associated with an increased risk of appendicular lower limb fractures (HR: 1.43; 95% CI: 1.30 to 1.57), upper limb fractures (HR: 1.29; 95% CI: 1.16 to 1.45), osteoporotic/fragility fractures (HR: 1.14; 95% CI: 1.02 to 1.28) and appendicular unspecified fractures (HR: 1.25; 95% CI: 1.05 to 1.48). Subgroup analyses indicated stronger associations in prospective studies. Women with T2D had a significantly higher fracture risk than men. Meta-regression analyses showed that a higher percentage of women participants and a longer duration of T2D were associated with stronger associations between T2D and fracture risk, particularly for lower limb fractures. CONCLUSION: T2D is associated with an increased risk of fractures, especially in lower limbs (hip, ankle and foot). These findings highlight the importance of targeted fracture prevention strategies and site-specific risk assessment for individuals with T2D. However, due to the heterogeneity among studies, caution is required in the interpretation of these findings.
2. Multi-omics analysis of dynamic profiles in response to various nutrient loads provides novel insights into obesity.
Postprandial multi-omics outperformed fasting measures in capturing obesity-related biology, highlighting pathways such as bile acid biosynthesis, triglyceride metabolism, and complement activation. Dietary habits and gut microbiota modulated acute responses; glucose produced the lowest acute obesity-risk signature among isocaloric macronutrients, and olive oil responses diverged by enterotype.
Impact: By integrating metabolomics, lipidomics, proteomics, hormones, and microbiome across dynamic postprandial states, this study reframes obesity assessment from static fasting snapshots to actionable, individualized response profiles.
Clinical Implications: Dynamic postprandial profiling may guide personalized nutrition (e.g., macronutrient composition) and identify patients whose microbiota predisposes to adverse metabolic responses, enabling targeted dietary intervention beyond fasting biomarkers.
Key Findings
- Postprandial multi-omic features associated more strongly with obesity than fasting measures.
- Pathways enriched across BMI strata included bile acid biosynthesis, triglyceride metabolism, and complement activation.
- Diet and gut microbiota shaped responses; glucose had the lowest AORS among isocaloric macronutrients, and olive oil responses varied by Bacteroides vs Prevotella enterotypes.
Methodological Strengths
- Prospective mixed-meal tolerance test with dense multi-omics time series and metagenomics
- Replication/contrast via single macronutrient challenge to derive an acute obesity-risk signature
Limitations
- SMNTT sample was small (n=24) and responses were acute; long-term outcomes not assessed
- Non-diabetic cohort limits generalizability to metabolic disease populations
Future Directions: Validate AORS against longitudinal metabolic endpoints and test microbiota-informed dietary prescriptions in randomized, genotype- and enterotype-stratified trials.
BACKGROUND& AIMS: Obesity is a global health issue driven by improper nutrient intake and metabolic dysregulation. The complexity of dietary components and the dynamic nature of postprandial metabolism limit our understanding of how different nutrient loads associated with obesity. This study aims to characterize the dynamic metabolic responses to nutrient intake using multi-omics approaches, assess the influence of dietary habits and gut microbiota, and evaluate the acute obesity-risk signature (AORS) associated with different macronutrients. METHODS: We conducted a mixed meal tolerance test (MMTT) in 147 non-diabetic individuals (54 controls, 38 overweight, 55 obese). Blood samples were collected at multiple time points for untargeted metabolomics, lipidomics, proteomics, and hormone assays. Gut microbiota was profiled via metagenomic sequencing. A separate single macronutrient tolerance test (SMNTT) involving glucose, whey protein, butter, and olive oil was performed in 24 healthy volunteers to compare acute metabolic responses and derive an AORS based on postprandial multi-omics data. RESULTS: Postprandial multi-omic analytes showed stronger associations with obesity indicators than fasting measures. Distinct temporal changes in metabolites, lipids, and proteins were observed across different BMI groups, with enrichment in pathways such as bile acid biosynthesis, triglyceride metabolism, and complement activation. Dietary habits and gut microbiota significantly influenced postprandial metabolic profiles, with specific metabolites and proteins mediating their effects on obesity. In SMNTT, glucose load exhibited the lowest AORS among isocaloric macronutrients (0.1082 ± 0.1917 %). Gut microbiota composition further modulated metabolic responses, with olive oil showing divergent AORS between Bacteroides- and Prevotella-dominated enterotypes (p = 0.043). CONCLUSION: Postprandial multi-omics provides superior insights into obesity pathophysiology compared to fasting measurements. Our findings reveal that dietary habits and gut microbiota significantly influence postprandial metabolism and obesity risk, and demonstrate that different macronutrients confer distinct AORS values, which are further modified by an individual's gut microbiota composition. This underscores the potential for personalized nutritional strategies based on dynamic metabolic responses and microbial ecology.
3. Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study.
In a matched real-world cohort of 88,940 adults with T2D, tirzepatide initiation was associated with substantially lower incident MCI compared with semaglutide, with less consistent signals for dementia and Alzheimer's disease. Results are hypothesis-generating and call for randomized trials with standardized cognitive endpoints.
Impact: This study expands incretin pharmacotherapy assessment to neurocognitive endpoints at scale, suggesting potential differential effects between tirzepatide and semaglutide that warrant confirmatory trials.
Clinical Implications: While not practice-changing yet, clinicians may consider the emerging neurocognitive signal when individualizing T2D therapy, especially in patients at high risk for cognitive decline, pending validation from randomized trials.
Key Findings
- After 1:1 propensity score matching (44,470 per group), tirzepatide was associated with lower incident MCI versus semaglutide (RR 0.12; 95% CI 0.06–0.22).
- Lower risks were also observed for all-cause dementia (RR 0.15; 95% CI 0.09–0.26) and Alzheimer's disease (RR 0.48; 95% CI 0.22–1.01), with weaker consistency.
- Absolute risks were low and survival curve separation was strongest for MCI; findings are hypothesis-generating.
Methodological Strengths
- Large-scale real-world dataset with rigorous 1:1 propensity score matching
- Time-to-event analyses with Kaplan–Meier estimation of incident neurocognitive diagnoses
Limitations
- Observational design with potential residual confounding and channeling bias
- Outcome misclassification possible due to reliance on coded diagnoses; follow-up ≥12 months may be insufficient for dementia endpoints
Future Directions: Conduct head-to-head randomized trials with standardized cognitive batteries and biomarker endpoints to test neurocognitive effects of incretin-based therapies and mechanisms (e.g., weight loss vs direct central actions).
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists have shown promise in managing type 2 diabetes mellitus (T2DM) and provide metabolic and cardiovascular benefits. Their associations with neurocognitive outcomes in clinical populations remain uncertain. METHODS: We conducted a retrospective, population-based cohort study using de-identified electronic health records from the global TriNetX research network, predominantly comprising U.S.-based healthcare organizations. Adults with T2DM who initiated tirzepatide or semaglutide were included. Propensity score matching (1:1) was applied to balance baseline characteristics, including age, sex, race, and cardiometabolic and psychiatric comorbidities. Incident diagnoses of mild cognitive impairment (MCI), dementia, and Alzheimer's disease (AD) occurring at least 12 months after treatment initiation were assessed using risk ratios (RRs) and time-to-event analyses with Kaplan-Meier estimators. FINDINGS: A total of 290,606 patients initiated semaglutide and 44,471 initiated tirzepatide. After propensity score matching, each group included 44,470 patients. Compared with semaglutide, initiation of tirzepatide was associated with a lower risk of MCI (RR 0.12; 95% CI 0.06-0.22), dementia (RR 0.15; 95% CI 0.09-0.26), and AD (RR 0.48; 95% CI 0.22-1.01). Absolute risks were low for all outcomes, and separation of survival curves was more consistent for MCI than for dementia or AD. INTERPRETATION: In this real-world observational analysis of adults with T2DM, initiation of tirzepatide was associated with a lower incidence of MCI compared with semaglutide, whereas associations for dementia and AD were less consistent. These findings should be interpreted descriptively and as hypothesis-generating. Prospective randomized trials with longer follow-up and systematic neurocognitive assessment are needed to clarify whether, and under which conditions, incretin-based therapies influence neurocognitive outcomes.